ARCHIVES

GSK’s Pazopanib Benefits Similar to Sunitinib; Sponsor Points to More Favorable Safety Profile

This article is from The Cancer Letter archive.

Vol. 36 No. 8 | August 30, 2013

Download PDF Visit The Full Archive

Related Articles

NCI Expects 200 CCP applications; Grand Rapids Workshop To Offer Last Chance to Ask Questions

September 24, 1982

DCT Board Okays $3 Million In New Programs, $8 Million In Recompetitions

October 24, 1980

Flexibility OK In Paying Grants If Justified, Upton Affirms

September 1, 1978

ACCC To Take In State Chapters, Forms Trials Group

April 6, 1990

ODAC’s Dilemma: Proposed Indication Created By Reliance On PSA Screening and Hormonal Treatment

September 23, 2011

Flood Mistrial

February 9, 1979